)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Implantica (IMP) investor relations material
Implantica Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Five-year pivotal study results for RefluxStop published, showing superior outcomes and safety versus existing treatments, with minimal side effects and unmatched efficacy across multiple centers and countries.
US FDA approval process for RefluxStop in final stages; Module 3 submitted, feedback expected in five weeks, inspections scheduled for October, and US launch preparations ongoing.
Revenue declined 22% year-over-year to €433,000 in Q2 due to focus on enrolling patients for a major randomized clinical trial; H1 sales rose 2% to €1.18m.
Expansion in Europe continues, with 19 centers in Spain and NICE recommending RefluxStop for NHS use in the UK for patients with ineffective esophageal motility.
Cash and short-term investments stood at €56.3 million at period end, with no interest-bearing debt.
Financial highlights
Net sales for the quarter were €433,000, down 22% year-over-year; H1 net sales were €1.18 million, up 2%.
Adjusted gross margin was 90% in Q2 (vs. 91% prior year); H1 margin rose to 94% (from 91%).
Operating loss decreased by 23% to €4.5 million in Q2; H1 EBIT loss reduced by 33% to €8.7 million.
Net cash outflow for the quarter was €3.9 million; H1 net cash outflow from operating activities was €8.44 million, improved from €13.0 million prior year.
No interest-bearing debt; equity ratio increased to 98%.
Outlook and guidance
FDA approval for RefluxStop anticipated by year-end or early next year, with US launch preparations including production ramp-up and surgeon training.
NICE recommendation expected to drive increased adoption in UK NHS hospitals, with commercial acceleration likely after summer.
Randomized controlled trial (RCT) of 200 patients starting imminently, with results expected within one year.
Revenue impact from RCT launch expected to ease as patient recruitment stabilizes.
Expansion into Canada and Japan expected to follow US approval.
What is the expected timeline for FDA module 3 feedback?
Assess the long-term financial impact of the RCT.
Explain the impact of NICE guidance on global policy.
Explain the rationale behind Spain's success.
Elaborate on the eHealth platform's licensing potential.
What's the timeline for RCT procedure completion?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Implantica earnings date
Q3 202531 Oct, 2025
Next Implantica earnings date
Q3 202531 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Implantica AG with headquarters in Horw/Luzern (Switzerland) is a company developing and distributing innovative solutions for reconstructive surgery. The company’s range of products includes implants based on the unique Zoladex® technology, which is used in a wide variety of applications such as industrial implants, biodegradable drug carriers and scaffolds. In addition Implantica provides best-in-class synthetic meshes for use in hernia repair procedures.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage